Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Sponsor: RAPT Therapeutics, Inc.
Summary
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
Official title: Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
323
Start Date
2018-09-25
Completion Date
2024-12-31
Last Updated
2026-09-03
Healthy Volunteers
No
Conditions
Interventions
FLX475 (tivumecirnon)
tablet
pembrolizumab (KEYTRUDA®)
IV infusion
Locations (35)
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles JCCC Clinical Research Unit
Los Angeles, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Georgetown - Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Comprehensive Hematology and Oncology, LLC
St. Petersburg, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory Winship Cancer Institute
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
University of Louisville Hospital/James Graham Brown Cancer Center
Louisville, Kentucky, United States
Johns Hopkins University
Baltimore, Maryland, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Quantum Santa Fe
Santa Fe, New Mexico, United States
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York, United States
Carolina BioOncology Institute
Huntersville, North Carolina, United States
Mary Crowley Cancer Research Center
Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
University of Washington
Seattle, Washington, United States
Austin Hospital
Heidelberg, Victoria, Australia
Linear Clinical Research Limited
Nedlands, Western Australia, Australia
Queen Mary Hospital - Lymphoma
High West, Hong Kong
Queen Mary Hospital
High West, Hong Kong
Prince of Wales Hospital
Shatin, Hong Kong
Seoul National University
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Chungbuk National University Hospital
Taebuk, South Korea
National Cheng Kung University Hospital
Tainan, Taiwan
Chi Mei Meidcal Center
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
King Chulaongkorn Memorial Hospital
Bangkok, Thailand
Ramathibodi Hospital
Bangkok, Thailand